The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser.
For the best experience on our site, be sure to turn on Javascript in your browser.
Cookie Policy:
This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy . By continuing to browse this site you agree to our use of cookies.
Continue
Select Country:
Argentina
Australia
Austria
Belgium
Bosnia and Herzegovina
Brazil
Canada
Chile
China
Colombia
Cyprus
Czech Republic
Denmark
Ecuador
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
India
Iran
Iraq
Ireland
Israel
Italy
Japan
Latvia
Lithuania
Luxembourg
Malaysia
Mexico
Netherlands
New Zealand
Norway
Other Country
Pakistan
Peru
Poland
Portugal
Romania
Russia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sweden
Switzerland
Syria
Taiwan
Thailand
Turkey
United Kingdom
United States
Uruguay
Venezuela
As low as
INQ
In stock
Only %1 left
SYN-1178-M001 1 mg CHF 128.00
SYN-1178-M005 5 mg CHF 170.00
SYN-1178-M010 10 mg CHF 454.00
SYN-1178-M050 50 mg CHF 1’348.00
SYN-1178-M100 100 mg INQ
More Information
Product Details
Synonyms
NVP-BEZ226; BEZ-226
Product Type
Chemical
Properties
Formula
C28 H25 F3 N6 O2 . C4 H4 O4
MW
534.5 . 116.1
CAS
1245537-68-1
Purity Chemicals
≥95%
Appearance
Solid.
Solubility
Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol.
Declaration
Manufactured by SynKinase.
Other Product Data
Target: PI3K | Kinase Group: Lipid Kinase | Substrate: LipidClick here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key
YUXMAKUNSXIEKN-BTJKTKAUSA-N
Shipping and Handling
Shipping
AMBIENT
Short Term Storage
+4°C
Long Term Storage
-20°C
Use/Stability
Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS
Download PDF
Product Specification Sheet
Datasheet
Download PDF
Description NVP-BGT226 is a novel, orally bioavailable small-molecule inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin with an IC(50) of 1nM.
Product References
Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma: P. Baumann, et al.; Anticancer Drugs 23, 131 (2012)
© 2017 Adipogen Life Sciences. Pictures:
© 2012 Martin Oeggerli. All Rights Reserved.